Akebia Therapeutics Inc
AKBA
View Detailed Chart
1.329USD
-0.060-4.35%
Market hours （ET）Quotes delayed by 15 min
24.31MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.35%
5 Days
-6.37%
1 Month
+1.49%
6 Months
-50.94%
Year to Date
-17.42%
1 Year
-30.39%
View Detailed Chart
TradingKey Stock Score of Akebia Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Akebia Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 74 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 4.40.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Akebia Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Akebia Therapeutics Inc Highlights
StrengthsRisks
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.36% year-on-year.
Undervalued
The company’s latest PE is -64.49, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 132.23M shares, increasing 1.10% quarter-over-quarter.
Held by Joel Greenblatt
Star Investor Joel Greenblatt holds 15.97K shares of this stock.
Analyst Rating
Based on
5
analysts
Strong Buy
Current Rating
4.400
Target Price
+216.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Akebia Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Akebia Therapeutics Inc Info
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Ticker SymbolAKBA
CompanyAkebia Therapeutics Inc
CEOButler (John P)
Websitehttps://akebia.com/
Related Instruments
+1.15%
-0.28%
+0.80%
+5.91%
-0.71%
+1.76%
+1.67%
+0.33%
-0.27%
+0.34%
-2.84%
+0.47%
+0.70%
+2.44%
-2.78%
0.00%
+0.23%
+1.88%
-0.54%
+1.93%Popular Symbols
246.419
-2.381 (-0.96%)
165.440
-2.080 (-1.24%)
66626.200
+42.150 (+0.06%)
252.125
-21.225 (-7.76%)
2028.910
+28.910 (+1.45%)
355.640
-6.190 (-1.71%)
4500.360
+7.840 (+0.18%)
102.452
+1.843 (+1.83%)
1.146
-0.004 (-0.39%)
159.623
-0.629 (-0.39%)
